Azathioprine and Mycophenolate Mofetil Adherence Patterns and Predictors Among Medicaid Beneficiaries With Systemic Lupus Erythematosus

Azathioprine (AZA) and mycophenolate mofetil (MMF) are immunosuppressants frequently used in the treatment of moderate‐to‐severe systemic lupus erythematosus (SLE). We studied longitudinal patterns and predictors of adherence to AZA and MMF in a nationwide US SLE cohort.

[1]  D. Isenberg,et al.  A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self‐Administered Questionnaires , 2018, Clinical pharmacology and therapeutics.

[2]  I. Kawachi,et al.  Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus. , 2018, Seminars in arthritis and rheumatism.

[3]  J. Yazdany,et al.  Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus , 2015, Arthritis care & research.

[4]  L. Magder,et al.  Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence , 2015, The Journal of Rheumatology.

[5]  J. Craig,et al.  Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus: A Systematic Review of Clinical Practice Guidelines , 2015, Arthritis care & research.

[6]  T. Brennan,et al.  Group-based Trajectory Models: A New Approach to Classifying and Predicting Long-Term Medication Adherence , 2013, Medical care.

[7]  Jinoos Yazdany,et al.  American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis , 2012, Arthritis care & research.

[8]  L. Chibnik,et al.  Identification and validation of lupus nephritis cases using administrative data , 2010, Lupus.

[9]  J. Benner,et al.  Comparing Adherence and Persistence Across 6 Chronic Medication Classes , 2009, Journal of managed care pharmacy : JMCP.

[10]  L. Trupin,et al.  Depression, medication adherence, and service utilization in systemic lupus erythematosus. , 2009, Arthritis and rheumatism.

[11]  M. Suarez‐Almazor,et al.  Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus , 2008, Clinical Rheumatology.

[12]  C. Anderson‐Cook,et al.  Group-Based Modeling of Development , 2006 .

[13]  D. Nagin.  Group-based modeling of development , 2005 .

[14]  M. Ward.  Development and testing of a systemic lupus-specific risk adjustment index for in-hospital mortality. , 2000, The Journal of rheumatology.

[15]  A V Prochazka,et al.  The assessment of refill compliance using pharmacy records: methods, validity, and applications. , 1997, Journal of clinical epidemiology.

[16]  T D Koepsell,et al.  A General Method of Compliance Assessment Using Centralized Pharmacy Records: Description and Validation , 1988, Medical care.